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Backgrounds/Aims: Despite advances in surgical techniques and perioperative supportive care, radical resection of 
hilar cholangiocarcinoma is the only modality that can achieve long-term survival. We chronologically investigated surgical 
and oncological outcomes of hilar cholangiocarcinoma and analyzed the factors affecting overall survival. Methods: 
We retrospectively enrolled 165 patients with hilar cholangiocarcinoma who underwent liver resection with a curative intent. 
The patients were divided into groups based on the period when the surgery was performed: period I (2005-2011) and 
period II (2012-2018). The clinicopathological characteristics, perioperative outcomes, and survival outcomes were ana-
lyzed. Results: The patients’ age, serum CA19-9 levels, and serum bilirubin levels at diagnosis were significantly higher 
in the period I group. There were no differences in pathological characteristics such as tumor stage, histopathologic status, 
and resection status. However, perioperative outcomes, such as estimated blood loss (1528.8 vs. 1034.1 mL, p=0.020) and 
postoperative severe complication rate (51.3% vs. 26.4%, p=0.022), were significantly lower in the period II group. 
Regression analysis demonstrated that period I (hazard ratio [HR]=1.591; 95% confidence interval [CI]=1.049-2.414; 
p=0.029), preoperative serum bilirubin at diagnosis (HR=1.585; 95% CI=1.058-2.374; p=0.026), and tumor stage (III, IV) 
(HR=1.671; 95% CI: 1.133-2.464; p=0.010) were significantly associated with poor prognosis. The 5-year survival rate 
was better in the period II patients than in the period I patients (35.1% vs. 21.0%, p=0.0071). Conclusions: The surgical and 
oncological outcomes were better in period II. Preoperative serum bilirubin and advanced tumor stage were associated 
with poor prognosis in patients with hilar cholangiocarcinoma. (Ann Hepatobiliary Pancreat Surg 2021;25:62-70)
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INTRODUCTION
Surgical resection is the only treatment modality that can 
achieve long-term survival outcomes after the treatment 
of hilar cholangiocarcinoma, a malignancy of the biliary 
epithelium of the hilum.1,2 Despite advances in surgical tech-
niques and perioperative supportive care, the treatment of 
hilar cholangiocarcinoma remains challenging. Due to its 
infiltrative nature by longitudinal extension and its prox-
imity to vital vascular structures, surgical resection of the 
tumor is limited and has unfavorable oncological outcomes.3,4 
Extended major hepatectomy with concomitant vascular 
and biliary resection and reconstruction is associated with 
high perioperative morbidity and mortality rates, and, as 
such, the evolution of surgical treatment for hilar cholan-
giocarcinoma is ongoing.
To date, the actual 5-year survival rate for hilar chol-
angiocarcinoma is 14%-45%.5,6 In addition, the prognostic fac-
tors affecting long-term survival include lymph node meta-
stasis, tumor resection margin status, and histological dif-
ferentiation.7,8 Multicenter studies have reported that the 
broad spectrum of oncological outcomes originates from 
the variation in follow-up periods, inclusion of palliative 
resection, and numerous surgical approaches. Furthermore, 
there have been limited reports on the chronological anal-
ysis of hilar cholangiocarcinoma.9,10
Therefore, in the current study, we aimed to chronolog-
ically investigate the surgical and oncological outcomes 
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Table 1. Comparison of the adjuvant chemotherapy regimens 








  No 42 (53.8%) 49 (56.3%)
  Yes 36 (46.2%) 38 (43.7%)
Capecitabine-based regimen 0.882
  No 74 (94.9%) 81 (93.1%)
  Yes 4 (5.1%) 6 (6.9%)
Fluorouracil-based regimen 0.437
  No 53 (67.9%) 53 (60.9%)
  Yes 25 (32.1%) 34 (39.1%)
Cisplatin-based regimen 0.480
  No 36 (46.2%) 46 (52.9%)
  Yes 42 (53.8%) 41 (47.1%)
of hilar cholangiocarcinoma using a single-center cohort 
and analyzed the factors affecting overall survival (OS).
MATERIALS AND METHODS
Patient population and classification of the 
chronological period
We retrospectively reviewed the medical records of 165 
patients who underwent surgical treatment with a curative 
intent for hilar cholangiocarcinoma from January 2005 to 
March 2018 at our hospital. The patients were divided in-
to two groups according to the period when they under-
went surgery: period I (2005-2011; n=78) and period II (2012- 
2018; n=87). The surgical treatment comprised liver resec-
tion, including more than three segments, with caudate lo-
bectomy and Roux-en-Y hepaticojejunostomy. The types 
of surgery were right hemihepatectomy and extended right 
hemihepatectomy, left hemihepatectomy and extended left 
hemihepatectomy, and central bisectionectomy.
The need for informed consent was waived due to the 
retrospective nature of the study and because anonymous 
clinical data were used for the analyses. The study was 
approved by the institutional review board of the hospital 
(approval number: 4-2020-0676).
Classification of hilar cholangiocarcinoma and 
perioperative management
The type of hilar cholangiocarcinoma was classified ac-
cording to the Bismuth-Corlette classification.11 The final pa-
thology and stage were analyzed according to the Ameri-
can Joint Committee on Cancer, 8th edition. R0 resection in-
dicates a microscopically margin-negative resection, in which 
there was no gross or microscopic tumor remaining at the 
primary tumor bed as described in the final pathologic 
report. R1 resection indicates the removal of all macro-
scopic diseases, but with microscopic margins positive for 
tumors. Postoperative complications were classified ac-
cording to the Clavien-Dindo classification.12 Postoperative 
liver failure was described in accordance with the classi-
fication criteria of the International Study Group of Liver 
Surgery.13
All patients underwent computed tomography (CT) and 
magnetic resonance imaging preoperatively. Portal vein em-
bolization for remnant liver volume expansion was per-
formed according to the remnant liver volume on CT scan- 
based liver volumetry before the planned surgery. The rem-
nant liver volume was re-evaluated using CT scans ob-
tained 2 weeks after porta vein embolization. If patients 
demonstrated severe obstructive jaundice with cholangitis, 
we considered preoperative biliary drainage, including 
percutaneous transhepatic biliary drainage, endoscopic ret-
rograde biliary drainage, and endoscopic nasobiliary drain-
age, depending on the situation. The standard serum bilir-
ubin level for performing radical resection is 3-4 mg/dl 
before surgery; however, this is based on the condition of 
the liver.
Surgical resection was performed by four surgeons in 
our institution. Major liver resections, including right hemi-
hepatectomy, extended right hemihepatectomy, left hemi-
hepatectomy, extended left hemihepatectomy, and central 
bisectionectomy, were performed using caudate lobectomy. 
For radical resection of the tumor, tumors that were visi-
ble by eye were removed, and examination of the prox-
imal and distal margins was performed using frozen sec-
tions. For lymph node resection, the hepatic and duodenal 
ligament lymph nodes, including the right side of the cel-
iac artery and the posterior pancreatic lymph nodes, were 
subjected to en bloc resection. The remaining lobe after 
resection was defined as the one with less bile duct in-
vasion and no hepatic artery invasion and leaving the lobe 
through which healthy bile is drained. A total of 19 pa-
tients underwent a concomitant major vascular resection, 
including hepatic artery/portal vein resection and recon-
struction. 
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  Male 45 (57.7%) 62 (71.3%)
  Female 33 (42.3%) 25 (28.7%)
Age (years) 62.2±10.0 65.6±8.6 0.021
Serum albumin (g/dl)  3.5±0.4  3.4±0.5 0.144
Serum bilirubin level at diagnosis (mg/dl)  7.6±6.8  5.0±5.6 0.008
Serum bilirubin level 1 day before surgery (mg/dl)  1.8±1.3  1.6±1.2 0.322
Serum AST (IU/L) 44.8±28.2 48.9±37.4 0.426
Serum ALT (IU/L) 51.1±67.4 51.8±66.2 0.946
Serum ALP(IU/L) 250.4±226.4 225.1±144.5 0.402
Serum GT (IU/L) 401.4±491.1 360.6±288.3 0.576
CA 19-9 level at diagnosis (U/ml) 1526.6±4076.9 603.0±1807.6 0.069
CA 19-9 1 day before surgery(U/ml) 1306.3±3856.3 362.1±884.9 0.039
Preoperative cholangitis 0.636
  No 33 (42.3%) 36 (41.4%)
  Yes 45 (57.7%) 51 (58.6%)
Decompression method 0.124
  None 15 (19.2%) 22 (25.3%)
  PTBD 41 (52.6%) 30 (34.5%)
  ERCP (ERBD or ENBD) 22 (28.2%) 35 (40.2%)
Bismuth-Corlette classification 0.239
  I 2 (2.6%) 4 (4.6%)
  II 11 (14.1%) 7 (8.0%)
  IIIa 29 (37.2%) 35 (40.2%)
  IIIb 10 (12.8%) 20 (23.0%)
  IV 26 (33.3%) 21 (24.1%)
Preoperative portal vein embolization 0.174
  No 62 (79.5%) 60 (69.0%)
  Yes 16 (20.5%) 27 (31.0%)
Neoadjuvant chemotherapy 0.709
  No 73 (93.6%) 79 (90.8%)
  Yes 5 (6.4%) 8 (9.2%)
Adjuvant chemotherapy 0.335
  No 26 (33.3%) 22 (25.3%)
  Yes 52 (66.7%) 65 (74.7%)
Adjuvant radiotherapy 0.951
  No 48 (61.5%) 55 (63.2%)
  Yes 30 (38.5%) 32 (36.8%)
Data are reported as mean±standard deviation or n (%)
AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; GT, gamma glutamyl transferase; CEA, 
carcinoembryonic antigen; CA 19-9, carbohydrate antigen; PTBD, percutaneous transhepatic biliary drainage; ERCP, endoscopic 
retrograde cholangiopancreatography; ERBD, endoscopic retrograde biliary drainage; ENBD, endoscopic nasobiliary drainage
Postoperative management of the patients was generally 
performed in the general ward. Pain was managed using 
patient-controlled epidural analgesia, and enteral feeding 
was started on postoperative day 3-5. All patients under-
went CT on postoperative day 5. After discharge, routine 
follow-up imaging was performed at an outpatient clinic 
and adjuvant therapy was considered depending on the fi-
nal pathology report.
Adjuvant treatment
According to the final pathologic report, patients with 
R1 resection or higher or T2 grade or higher or those who 
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Table 3. Comparison of the type of surgery between the two 







Type of operation 0.015
  Right 
  hemihepatectomy
42 (53.8%) 49 (56.3%)
  Extended right 
  hemihepatectomy
1 (1.3%) 4 (4.6%)
  Left 
  hemihepatectomy
27 (34.6%) 32 (36.8%)
  Extended left 
  hemihepatectomy
8 (10.3%) 0 (0.0%)
  Central 
  bisectionectomy
0 (0.0%) 2 (2.3%)
Hepatic artery resection 0.531
  No 76 (97.4%) 82 (94.3%)
  Yes 2 (2.6%) 5 (5.7%)
Portal vein resection 1.000
  No 72 (92.3%) 81 (93.1%)
  Yes 6 (7.7%) 6 (6.9%)
were positive for retrieved lymph nodes underwent ad-
juvant chemotherapy. The regimen was selected according 
to the physician’s preference and/or the patient’s condition. 
The distribution of the main regimen according to period 
is summarized in Table 1.
Statistical analysis
Descriptive analyses of the clinical data were conducted 
using Student’s t-test and Pearson’s chi-square test. OS 
was analyzed using the Kaplan-Meier method, and stat-
istical differences were calculated using the log-rank test. 
OS was calculated from the day of surgery to death or 
the last follow-up. Statistical significance was set at p＜ 
0.05. Cox proportional hazards regression models were 
used to determine the association between patient charac-
teristics and OS. All results, except OS analysis, are pre-
sented as mean and standard deviation with percentages. 
The analysis of OS is presented with the median survival 
(month). To reduce selection bias and the effect of poten-
tial confounders, predictive factors were calculated using 
logistic regression based on age, sex, etiology, surgical 
procedure, and American Joint Committee on Cancer 
stage. All statistical analyses were performed using SPSSⓇ 
for Windows version 22.0 (IBM Corp., Armonk, NY, USA).
RESULTS
Clinical characteristics according to the period
In both periods, the patients were predominantly male. 
The mean patient age was 62.2 and 65.6 years in period 
I and period II, respectively (p=0.021). There were no sta-
tistically significant differences in terms of liver profile la-
boratory findings, except serum bilirubin level at diag-
nosis (7.6±6.8 vs. 5.0±5.6 mg/dl, p=0.008). The mean serum 
CA19-9 level 1 day before surgery was significantly high-
er in period I than in period II (1306.3 vs. 362.1 U/ml, 
p=0.039). 
Preoperative percutaneous transhepatic biliary drainage 
and endoscopic biliary drainage were performed in 63 pa-
tients (80.8%) and 65 patients (74.7%) in periods I and II, 
respectively. There were no significant differences in the 
type of hilar cholangiocarcinoma and the proportion of pre-
operative portal vein embolization between the two periods. 
Adjuvant chemotherapy (66.7% vs. 74.7%, p=0.335) and 
adjuvant radiotherapy (38.5% vs. 36.8%, p=0.951) were 
performed during period I and period II (Table 2).
Extent of surgery and concomitant resection
During period I, 43 patients (53.8%) underwent right 
hemihepatectomy, 35 patients (44.9%) underwent left hemi-
hepatectomy, and 8 patients (10.3%) underwent extended 
left hemihepatectomy. Further, two patients underwent 
hepatic artery resection and six patients underwent portal 
vein resection. During period II, 53 patients (59.9%) un-
derwent right hemihepatectomy, of whom, 4 patients (4.6%) 
underwent extended right hemihepatectomy. None of the 
patients underwent extended left hemihepatectomy. Central 
bisectionectomy was performed in two patients (2.3%), 
hepatic artery resection was performed in five patients 
(5.7%), and portal vein resection was performed in six pa-
tients (6.9%) (Table 3).
Pathologic characteristics
The final pathologic report for the entire study period 
was classified according to American Joint Committee on 
Cancer, 8th edition. Regarding T stage, T2b was the most 
common (53.8% vs. 50.6%), followed by T2a (38.5% vs. 
31.0%) in period I and period II. During both periods, 
three patients with no residual tumor in the resected speci-
men received neoadjuvant chemoradiotherapy. There were 
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Table 4. Comparison of the pathologic characteristics be-








  No residual tumor 0 (0.0%) 3 (3.4%)
  1 3 (3.8%) 6 (6.9%)
  2a 30 (38.5%) 27 (31.0%)
  2b 42 (53.8%) 44 (50.6%)
  3 1 (1.3%) 4 (4.6%)
  4 2 (2.6%) 3 (3.4%)
Number of positive 
lymph nodes 
1.0±1.7 0.8±1.5 0.437




  0 44 (56.4%) 57 (65.5%)
  1 27 (34.6%) 23 (26.4%)
  2 7 (9.0%) 7 (8.0%)
AJCC stage 0.104
  No residual tumor 0 (0.0%) 3 (3.4%)
  I 2 (2.6%) 4 (4.6%)
  II 42 (53.8%) 47 (54.0%)
  IIIa 0 (0.0%) 5 (5.7%)
  IIIb 0 (0.0%) 1 (1.1%)
  IIIc 27 (34.6%) 20 (23.0%)
  IVa 7 (9.0%) 7 (8.0%)
Cell differentiation 0.291
  No residual tumor 0 (0.0%) 3 (3.4%)
  Well differentiated 11 (14.1%) 9 (10.3%)
  Moderately 
  differentiated 
56 (71.8%) 66 (75.9%)
  Poorly differentiated 11 (14.1%) 9 (10.3%)
Microvascular invasion 0.414
  No 30 (38.5%) 40 (46.0%)
  Yes 48 (61.5%) 47 (54.0%)
Perineural invasion 1.000
  No 11 (14.1%) 13 (14.9%)
  Yes 67 (85.9%) 74 (85.1%)
Resection status 0.174
  R0 62 (79.5%) 60 (69.0%)
  R1 16 (20.5%) 27 (31.0%)
Data are reported as mean±standard deviation or n (%)
AJCC, american joint committee on cancer
Table 5. Comparison of the perioperative outcomes between 







Hospital stay (days) 29.6±19.8 27.8±46.5 0.748




  No 30 (38.5%) 61 (70.1%)




  None 27 (34.6%) 36 (41.4%)
  Grade A 33 (42.3%) 35 (40.2%)
  Grade B 12 (15.4%) 13 (14.9%)




  None 23 (29.5%) 44 (50.6%)
  Grade I 9 (11.5%) 11 (12.6%)
  Grade II 6 (7.7%) 9 (10.3%)
  Grade IIIa 26 (33.3%) 14 (16.1%)
  Grade IIIb 2 (2.6%) 2 (2.3%)
  Grade IVa 4 (5.1%) 0 (0.0%)
  Grade IVb 1 (1.3%) 3 (3.4%)
  Grade V 7 (9.0%) 4 (4.6%)
30-day mortality 0.614
  No 72 (92.3%) 83 (95.4%)
  Yes 6 (7.7%) 4 (4.6%)
no significant differences in the number of positive lymph 
nodes and retrieved lymph nodes between the two periods. 
The proportion of node metastasis was 43.6% during peri-
od I and 34.4% during period II. Further, 27 (34.6%) and 
26 (29.8%) patients had stage III cancer during period I 
and period II, respectively. R0 resection was performed 
in 60 patients (79.5%) in period I and 60 patients (69%) 
in period II. There were no statistically significant differ-
ences between the two periods in terms of T stage, N 
stage, cell differentiation, and histopathologic character-
istics (Table 4).
Perioperative outcomes
There was no significant difference in hospital stay be-
tween the two periods. The estimated blood loss was signi-
ficantly lower during period II than during period I (1528.8 
vs. 1034.1 ml, p=0.020). The proportion of patients who 
were transfused intraoperatively was also lower during pe-
riod II than during period I (61.5% vs. 29.9%, p＜0.001). 
The postoperative complications were lower during period 
II than during period I (p=0.022). In both periods, Clavien- 
Dindo grade IIIa complication was the most common (33.3% 
vs. 16.1%). Post-hepatectomy liver failure was not sig-
nificantly different between the two periods (p=0.594). Re-
garding postoperative 30-day mortality, six (7.7%) pa-
tients in period I and four (4.6%) patients in period II died 
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Table 6. Univariate and multivariate regression analyses of prognostic factors for overall survival
Variables
Univariate Multivariate analysis
p-value HR p-value HR 95% CI
Period I 0.009 1.741 0.029 1.591 1.049-2.414
Sex (male) 0.098 1.744
Age (＞60 years) 0.783 1.003
Preoperative serum albumin 
(＜3.5 g/dl)
0.195 1.529
Preoperative serum bilirubin at 
diagnosis (＞3 mg/dl) 
0.021 1.605 0.026 1.585 1.058-2.374
Preoperative serum CA 19-9 at 
diagnosis (＞400 U/ml)
0.009 2.590 0.182 1.322 0.877-1.991
Preoperative cholangitis 0.263 0.800
Right hemihepatectomy 0.815 0.955
Estimated blood loss (＞1000 ml) 0.284 1.234
Transfusion 0.224 0.786
Postoperative liver failure (PHLF B, C) 0.513 0.773
R status (R1) 0.688 0.911
MVI 0.142 0.746
PNI 0.455 0.816
Lymph node metastasis 0.033 1.522 0.591 1.788 0.330-1.882
Adjuvant chemotherapy 0.083 1.447 0.092 1.059 0.452-1.062
Adjuvant radiotherapy 0.294 0.810
Tumor stage (III, IV) 0.006 1.724 0.010 1.671 1.133-2.464
CA 19-9, carbohydrate antigen 19-9; MVI, microvascular invasion; PNI, perineural invasion; HR, hazard ratio; CI, confidence interval
Fig. 1. Overall survival analysis according to period.
(Table 5).
Survival analysis according to the period, and 
cox regression analysis of factors affecting OS
The median survival duration was 25 months (95% con-
fidence interval [CI]=19.807-30.193) and 42 months (95% 
CI=27.540-56.460) in period I and period II, respectively. 
The 5-year survival rate was 21.0% and 35.1% in period 
I and period II, respectively. The difference in survival 
duration was statistically significant (p=0.0071) (Fig. 1).
The univariate and multivariate analyses of factors re-
lated to survival are summarized in Table 6. During peri-
od I (hazard ratio [HR]=1.591; 95% CI=1.049-2.414; p= 
0.029), preoperative serum bilirubin level at diagnosis (HR= 
1.585; 95% CI=1.058-2.374; p=0.026), and tumor stage 
(III and IV) (HR=1.671; 95% CI=1.133-2.464; p=0.010) 
were significantly associated with poor prognosis. Preop-
erative serum CA 19-9 level, lymph node metastasis, and 
adjuvant chemotherapy were significant in univariate anal-
ysis but not in multivariate analysis.
DISCUSSION
Despite the efforts to improve the oncological outcome 
of hilar cholangiocarcinoma, the actual 5-year survival 
rate has remained low at 14%-45%.14 In our series, the 
5-year survival rate was 35.1% in the period II group and 
21.0% in the period I group. Several studies have reported 
chronological improvement and evolution in the surgical 
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and oncological outcomes of hilar cholangiocarcinoma.15,16 
Significant improvements were observed as the period pro-
gressed; however, the gap between the two periods is ＞25 
years. Since the investigated period is long, the analysis 
of contributing prognostic factors can be strongly influ-
enced by various biases. Therefore, it is necessary to ana-
lyze the change over a relatively short period and inves-
tigate the changes caused by the differences. In this series, 
we set the analyzing and comparing period as 6 years.
We found that period I was a significant prognostic fac-
tor for OS. The significant difference in OS between peri-
ods I and II may have resulted from the operative factors 
and perioperative support. These chronological and onco-
logical improvements in patients with surgically resected 
hilar cholangiocarcinoma have been shown in previous 
studies.9,17 Compared to patients in the period I group, 
those in the period II group had lower serum CA 19-9 
levels immediately prior to the surgery. Although there 
was no statistically significant difference between the two 
groups, the higher proportion of preoperative cholangitis 
and neoadjuvant chemotherapy in the period II group may 
have affected the preoperative CA 19-9 levels. Three pa-
tients who received neoadjuvant chemotherapy reported 
no residual tumor in the final pathologic report. Regarding 
intraoperative factors, the number of extended right hemi-
hepatectomies and central bisectionectomies in the period 
II patients was significantly higher than that in the period 
I patients, whereas extended left hemihepatectomy was per-
formed more frequently in the period I patients. Neverthe-
less, there were no significant differences in terms of hos-
pital stay, postoperative 30-day mortality, and postoperati-
ve liver failure rate; however, the period II group showed 
better outcomes in terms of estimated blood loss and the 
blood transfusion and postoperative complication rates. Pre-
vious studies have reported that operative morbidity and 
oncological outcomes of biliary-pancreatic malignancy are 
associated with intraoperative blood loss and blood 
transfusion.18-20 The association between blood transfusion 
and long-term survival after resection for perihilar chol-
angiocarcinoma has been examined previously.9,21 The 
specific mechanism leading to the adverse effect of blood 
transfusion is unclear, but experimental and clinical stud-
ies have demonstrated that blood transfusion suppresses 
host immunity by reducing natural killer cell activity and 
cytotoxic T cell function. 
Regarding radical resection status, the R0 resection rate 
of the period II group was lower than that of the period 
I group. Several previous studies that conducted a chrono-
logical analysis of the surgical outcomes following the 
treatment of perihilar cholangiocarcinoma reported that 
the R0 resection rate was 73%-79%.9,15-17 Since the pre-
vious studies included all R2 status, the ratio will be low-
er in the comparison between R0 and R1 only. However, 
the rate of R0 resection increased as the period progressed. 
In the current study, the spectrum of patients was clin-
ically expanded with the results from increased proportion 
of portal vein embolization and adjuvant therapy. In addi-
tion, ratio of Bismuth type III-IV (83.3% vs. 87.3%) in 
the preoperative diagnosis was increased. 
Preoperative serum bilirubin levels, which are known 
to reflect liver status and surgical extension,8 were also 
an important factor for OS in this study; however, there 
was no significant difference in bilirubin levels in the be-
tween-period comparison. The presence of lymph node 
metastasis is an important independent predictor of long- 
term survival,5,22 although it showed no statistical signi-
ficance. However, among the TNM stages, which are ex-
tended concept including tumor extent and lymph node 
metastasis, advanced stage (III and IV) was an important 
prognostic factor.
In recent years, surgical treatment for hilar cholangio-
carcinoma has been evolving steadily, with an expanded 
indication, decreased mortality, and increased survival. Pre-
vious studies have reported lymph node metastasis, histo-
pathologic status, resection margin status, and adjuvant che-
motherapy as important prognostic factors for resected hi-
lar cholangiocarcinoma.22-25 Recently, studies on neoadju-
vant therapy have been conducted as a bridge modality 
to improve the rate of radical resection of locally advan-
ced hilar cholangiocarcinoma.26-28 In view of these trends, 
especially those from 2000, the impact of surgical skills 
and methods remains important; however, the perioper-
ative support and management are also thought to contrib-
ute to the oncological outcomes in patients with hilar chol-
angiocarcinoma.
In conclusion, the surgical and oncological outcomes 
have improved in patients with hilar cholangiocarcinoma, 
and the survival rate is expected to improve in the coming 
years, including that of patients with radical and con-
comitant vascular resections. The liver status, predicted by 
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preoperative serum bilirubin levels, and advanced tumor 
stage, including tumor extension, are associated with poor 
prognosis in patients with hilar cholangiocarcinoma. How-
ever, there is limited evidence to accurately predict the 
prognosis with the currently known factors, and it is im-
portant to select a surgical candidate in consideration of 
the preoperative liver status and tumor extension.
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